Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (NCT04655976)
A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)
🩺 Plain-English Summary (8th-Grade Level)
This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (163 Sites)
Showing the first 25 of 163 sites.
- GSK Investigational Site — Fountain Valley, California
- GSK Investigational Site — Walnut Creek, California
- GSK Investigational Site — Norwich, Connecticut
- GSK Investigational Site — Washington D.C., District of Columbia
- GSK Investigational Site — Honolulu, Hawaii
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Edgewood, Kentucky
- GSK Investigational Site — Las Vegas, Nevada
- GSK Investigational Site — Mineola, New York
- GSK Investigational Site — New York, New York
- GSK Investigational Site — White Plains, New York
- GSK Investigational Site — Pittsburgh, Pennsylvania
- GSK Investigational Site — Pittsburgh, Pennsylvania
- GSK Investigational Site — Sioux Falls, South Dakota
- GSK Investigational Site — Houston, Texas
- GSK Investigational Site — Fredericksburg, Virginia
- GSK Investigational Site — Tacoma, Washington
- GSK Investigational Site — Buenos Aires,
- GSK Investigational Site — Cipoletti Rio Negro,
- GSK Investigational Site — Ciudad Autonoma de Buenos Aire,
- GSK Investigational Site — Florida,
- GSK Investigational Site — La Rioja,
- GSK Investigational Site — Pergamino,
- GSK Investigational Site — Rosario,
- GSK Investigational Site — Viedma,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lung Cancer, Non-Small Cell
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer — Plantation, Florida
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) — Ocala, Florida
- A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs — Dothan, Alabama
Explore by condition: All Lung Cancer, Non-Small Cell clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.